Data from molecular analyses unveil diverse resistance mechanisms to endocrine therapy in breast cancer
Among the presented findings, a potential role for ESR1 gene fusions was observed
Innovation is leading to a comprehensive ‘map’ of tumours
Advances in spatial transcriptomics could provide novel opportunities for early detection, metastasis prediction and identification of actionable targets
Adjuvant immunotherapy continues to confirm its efficacy in melanoma
Updated data from two studies report significant improvements in recurrence-free survival and distant-metastasis free survival with pembrolizumab or nivolumab
Immunotherapy
The expanding toolbox for immuno-oncology
Novel treatment approaches show encouraging early results in solid tumours, but ways to boost precision immunotherapy are needed
A c-Met directed antibody-drug conjugate shows preliminary activity in a NSCLC cohort
Efficacy and safety of telisotuzumab adizutecan was investigated in patients with EGFR wild type non-squamous disease
Cancer Control Principles
Off-label use of cancer medicines: an option not without challenges
Together with an off-trial use and off-track access to oncology therapies, a consolidated trend is reported in clinical practice despite the uncertainties on efficacy and safety
How to bridge the gap between palliative care and oncology?
Evidence from well-designed clinical trials is key to promote greater acceptance and access to palliative care
Frontline abemaciclib plus endocrine therapy showed superior efficacy compared to chemotherapy in aggressive HR+/HER2– breast cancer
The combination therapy with the CDK 4/6 inhibitor improved overall response rate compared to standard treatment
Promising antitumour activity presented for emerging targets in different solid tumours
Strategies to target MTAP deletion, KRAS G12D and ESR1 mutations, and CDK4 and CDK2 further expand the landscape of precision oncology
Drug Rediscovery Protocol-like Clinical Trials facilitate access to precision oncology
Data from studies presented highlight the importance of integrating and incorporating comprehensive genomic profiling into clinical practice across a broad range of tumour types